04:24 PM EST, 02/23/2026 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported a Q4 non-GAAP net loss late Monday of $0.14 per diluted share, widening from a loss of $0.07 a year earlier.

Analysts polled by FactSet expected a loss of $0.09.

The biopharmaceutical company did not report any revenue.

The company reported cash, cash equivalents and short-term investments of $713.4 million as of Dec. 31, up from $412.3 million a year earlier.